PharmaCorp Rx (PCRX) Q4 2025 earnings summary

Executive summary

• Fourth quarter 2025 revenue rose 75% year-over-year to $7.7 million, with fiscal year revenue up to $20.9 million from $5.8 million in 2024.

• Gross profit for Q4 2025 increased 78% year-over-year to $2.9 million, with a margin of 39%.

• Adjusted EBITDA for fiscal 2025 was $3.5 million, up from $0.85 million in 2024.

• Net loss for Q4 2025 was $0.64 million, an 11% improvement from Q4 2024; fiscal year net loss increased to $1.4 million due to credit agreement and acquisition-related expenses.

• Cash balance at year-end 2025 was $25.9 million, up from $12.9 million at the end of 2024.

Financial highlights

• Q4 2025 same-store sales grew 6% year-over-year; same-store prescription sales rose 3.8%.

• Fiscal year 2025 gross profit reached $8.3 million, up from $2.2 million in 2024.

• Operating expenses for fiscal 2025 were $3.6 million, with salaries, wages, and benefits at $3.57 million.

Outlook and guidance

• Management expects continued business scaling through disciplined M&A and integration of acquired stores.

• Ongoing interest from independent pharmacy owners is expected to drive further M&A opportunities in 2026.